Cargando…
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
BACKGROUND AND AIMS: Coronavirus disease 2019 (COVID-19) imposes a substantial and ongoing burden on the US healthcare system and society. Molnupiravir is a new oral antiviral for treating COVID-19 in outpatient settings. This study evaluated the cost-effectiveness profile of molnupiravir versus bes...
Autores principales: | Goswami, Hardik, Alsumali, Adnan, Jiang, Yiling, Schindler, Matthias, Duke, Elizabeth R., Cohen, Joshua, Briggs, Andrew, Puenpatom, Amy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9270266/ https://www.ncbi.nlm.nih.gov/pubmed/35779197 http://dx.doi.org/10.1007/s40273-022-01168-0 |
Ejemplares similares
-
Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
por: Goswami, Hardik, et al.
Publicado: (2023) -
Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective
por: Alsumali, Adnan, et al.
Publicado: (2021) -
Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023) -
Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin
por: Wehler, Elizabeth, et al.
Publicado: (2020) -
Molnupiravir: First Approval
por: Syed, Yahiya Y.
Publicado: (2022)